COMP <GO>
GMAB vs MRK // FORWARD P/E MULTIPLE
Genmab A/S ADS (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: GMAB 4
— MRK 11
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $57.06 (+1.01%) • MKT CAP: $35.25B
forward-pe
27.6x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMAB VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMAB | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 20.70% | -10.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 15.3x | +5.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 3.42% | -1.21 | MRK | /fcf-yield <GO> |
| Operating Margin | 13.90% | 34.30% | -20.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 28.10% | -17.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 1.30% | +20.70 | GMAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 5.19 | -1.45 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GMAB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 87.6 | 56.9 | +30.71 | GMAB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.92 | +0.17 | GMAB | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 27.6x | 18.4x | +9.20 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.25B | $361.02B | -$325.77B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMAB REV | MRK REV | GMAB GROSS % | MRK GROSS % | GMAB FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $65.01B | — | 74.8% | — | $12.36B |
| FY 2024 | — | $64.17B | — | 76.3% | — | $18.10B |
| FY 2023 | — | $60.12B | — | 44.0% | — | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMAB // BETA 1.09
MRK // BETA 0.92